HyQvia is the only up to once monthly (every 2, 3 or 4 weeks) immunoglobulin subcutaneous infusion to treat CIDP in Canada TORONTO, March 27, 2025 /CNW/ - Takeda Canada Inc. (Takeda) is pleased to ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Takeda Pharmaceutical’s Hyqvia, coformulated with Halozyme's Enhanze drug delivery ...
Overview: HyQvia is an injection given under your skin for certain immune system problems or inflammatory conditions. Common side effects can include pain, itching, swelling, or redness near where you ...
U.S. PI patients on Medicare now covered to self-administer HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] at home Baxalta continues to expand access to HYQVIA as ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and ...
Dedicated Devices for HYQVIA [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase] Reduce the Number of Steps and Ancillary Supplies Compared to a Pooling Bag When Preparing the ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced full results from the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial investigating HYQVIA® [Immune Globulin ...
Findings showed a statistically significant difference in relapse rates indicating that HyQvia was superior to placebo in preventing relapse of CIDP. The Food and Drug Administration (FDA) has ...
Takeda kicked off 2024 by reeling in an approval for HyQvia in chronic inflammatory demyelinating polyneuropathy (CIDP), and it’s closing out the year by launching its first direct-to-consumer ...
HYQVIA (immune globulin [human] 10% with recombinant human hyaluronidase) by Baxter and Halozyme The ADVANCE-1 trial included adults with a confirmed diagnosis of CIDP who had remained on a stable ...
DEERFIELD, Ill. and SAN DIEGO, Calif., July 31, 2014 - Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the Blood Products Advisory Committee ...
DEERFIELD, Ill. & SAN DIEGO--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the United States Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results